lawpalyer logo
in判決書

臺灣雲林地方法院110年度公字第1號

關鍵資訊

  • 裁判案由
    損害賠償
  • 案件類型
    民事
  • 審判法院
    臺灣雲林地方法院
  • 裁判日期
    111 年 07 月 12 日

  • 當事人
    (如附表一)

1101 111531: : 102582101151724 262934282910711091030 109327282957-63 11201010102829 1312 213511153114116-117 24916 1701731751 445-463 : 5 82557-558 8881293066201 387431,684148971,4276,08914,565 2,8095645 3559-57897沿101 83105 5 5 1841 Scheff and Porter 1991659-666 5 579-594 561-61910211510200035 595-596 西2001西2004PM2.5PM2.512667-693 沿98使255 132 10(PM10)2.5(PM2.5)1912PAHs9780170 102沿 10A滿35 (西0000-0000 西0000-00002.82353.54 35C9.048410 104 104 1,3-1,2-1,3-2-- 1,2-1,1,2,2-38725 36429 447 5 [a] International Agency for Reserch on CancerIARC1 carcinogenic to humans; 2A probably carcinogenic to humans; 1,2 - 1,1,2,2-2Bpo ssibly carcinogenic to humans RCA 5 4475 5 1842 1: 91663 103227: 221 使 2022223 202243223 232 1 1 42調 5 118491-5195 5 5 5 5 5 5 5 5 1842 5 1851671737 5 5 5 5 5 5 5 5 5 5 5 1913 1913使( 使使使使使2050 5 51185 1052,0005 使5 1913 5 1073 277 8929277 277使 277調 使 調 107267 ABRCA IARCU.S.EPACDC RCA RCA RCA 277 91223 調 101 101010西10202030調1)10SO3SO 西SOSOSO75 ppb(2) 西3)10PAHs5 AntChryFIPhePyrPAHs 95As)Ba)(Co)(Cr)(Li)(Mn)Rb)Sr)901)10西0000-0000西0000-00004.07102020302)尿(V)1- 1-OHP 3)1 ng/m³V)尿0.38 μg/g-cre atinine 1pyrene (ng/m³尿0.391-1-OHPμ mol/mol-creatinine839-10 1026.15 84215-21685-87( 10西20 (西( (10 西( 尿1-OHP西 (西 5 5 5 5 5 954 5 5 5 19419513使51223 195192164 5 195 : 1-232920 197-241263-319319-325335-359 1941953550 24-34 323-344361-36719515130 : 5 1951520 5 5 222 5 5 5 5 RCA RCA使 RCA 5 使 51045 471.765 西5 1.27×10西 1.64×105 5 104 西 5 使5 5 191355 5 1107275200 434284363 5 104 使使SPECIATE50497-2 5 104 5 10 4647104 10 485 1.27×l0 西1.64×l0 5 西5 5 使191 35104 調1.4.使使497-67-7調1913 56-10121729 6 10751 107524273217 7 10572888: Lung cancer813305221Lung cancer)598-10 105213313227 29 1024291025213152316012-13 10442228319241 14 10710515Cholangiocarcinoma18335-341319Cho1angiocarcinoma61 15-16 1071227 10811 Hepatocellulr carcinoma 343-34932162 17 108122108125Multiple myeloma351-359325(Multiple myeloma)63 30 323373416465 5 161171483 西 5IARC2A2B IARC2A2B1RCAIARC704-5 1031105545RCA 104505RCA IARC2A2B UNECE IARC Group2Btalc-based body powder6667) DuPont使IARC2BPF0APerfluorooctanoic AcidPF0A6869 IARC Sufficient evidencelimited evidence IARC2A2B52A2B l×10l0 9810451 5 西 l×10 103710372-53 10 1010 732-53 10211810 94314 8 l×10 17 l×10 1 7417 RCA 14.3104 1062012 756 76) 10 55 l×10 WHO西 l×10. WHO WHO2017Guidelines for drinking-water qualityWHO 10調disability-adjusted life year; DALY調DALY1070 101 7738 西 西2011Toxicological Intake Values for Priority Contaminants in Soil1.1.2 Acceptablerisk level 西使101 (Ministry of Health,MoH)1995 (Ministr y for the EnvironmentMfE) Ministry of Health, MoH), 1997(Ministry of Health, MoH),2005便 使10 7834 Health Canada 21FEDERAL CONTAMINATED SITE RISK ASSESSMENTIN CANADA PART IGUIDANCE ON HUMAN HEALTH PRELIMINARY QUANTITATIVE RISK ASSESSMENT (PQRA) Version 2.0""de minimu sincremental 1ifetime cancer riskILCR101l×10)7923 81301996130() 10 804 2017531 使101010 814 l×10 ""82) l×10 l×10 10 WHO西10 10 使l×10 l×10 9949954 2-4110 10 10 8398l×10 98-1045 西9899101 20X2030X30 5 78.0736524381044-54 ISC 4.2 10 RCA RCA 78.07 4050%1010 540-50% 5 5 4050% 540%1 010 5 5 10 5 5 10151036 8449.6-193.6 ppb(max) 1.77-3.76 ppb (100102103511.00260.96110.59740.03780.03440.024785) 1.770.03780.03440.024746-71 5 5 西5 西 5104使西 104 25055鹿 5 西使 2015 365340315294209201611512 133510Julieta 86) 19722 011Trachea, bronchu s & lung 5 10961794 107 5西 94107西 423 5西 51045 5 10西184121851913194195135 : 5 5 : 5 24412 使26611 106482 184 118421951 195192164 10732441231952 5 5 10西184121851913194195135 195 934 931015106 5 24412 277 使調107267 5 277 ( 1842191318425 5 5 1913 使使使 1913使91932 10200081106 427 5535548120.9910636.938121.9210636.979699100 使西94107 西西5 調 104 調調5 1001082291尿尿5 5 5 8 5 94104 94104 西10269410410 5 5 5 5 RCA 5 5 5 5 33355 使 1092125RCAIARC6810131517192 1232931333940-141 711 1216203032402240-242) 43 使西西西 5 5 IARC使 104RCA191319135 1913 使 326 8619131.2.32684 32693 使 1913331913 使 34使 1913 1078031913使使使使28 5使 9111541913191 335)5 5 191319131.2.32684 5 5 19131913 西西 8894415108530 358798868748738793470-471594 西 C52 1 1999200120082010 西20000.150.140.14 104 20002 100000-0000 0000-00004.0710 202030 51 40385 IARC)112PAHs51115 38261 1 - IARC1 5 51913 4038IRAC5111IARC5- IARC434 IARC1 IARC2A2BIARC2A2BIARC1 5111115 5 IARC1 IARCIARC 465RCA473 480 / RCA 40 480 調Polycyclic Aromatic Hydrocarbons, PAHs綿綿 RCA 使() IARCIARC 2012116 1 1 1 IARC1 1913 401115 4 U.S.EPA0.002mg/L Occupational Safety and H ealth AdministrationOSHA1 ppm Food and Drug Administration FDA調 8PEL-TWA 1 ppm2.6 mg/m3 5 Occupational Safety and H ealth Administration, 0SHA 1,3- 1 ppm 1,3-8(PEL-TWA)5 ppm11 mg/m3 6 U.S.EPA 5 ppbparts per billion Occupational Safety and Healt h Administration, OSHA8401 ppm pa rts per million 8PEL-TWA1 ppm3.2 mg/m3 7 U.S.EPA 1 mg/L105 mg/LU.S.EPA1 mg/L Occupational Safety and H ealth AdministrationOSHA8 400.75 ppm 8 PEL-TWA1 ppm1.2 mg/m3 8 8PEL-TWA1ppm1.8 mg/m3 9 PAHs10 Occupational Safety and Health AdministrationOSHAPAHs0.2 mg/m3PAHs5 mg/m38 The National Institu-te for Occupational Safety and Health, NIOSH1040PAHs0.1 mg/m3 PAHs 11 U.S.EPA 使U.S.EPA 0.01 ppm Occupational Safety and Health AdministrationOSHA840 PEL10 μg /m3 U.S.EPA Tolerable Daily IntakeTDI0.0003 mg/kg/day 600.018 mg 8PEL-TWA0.01 mg/m30.5 mg/m3 12 U.S.EPA0.04 ppm 10U.S.EPA0.005ppm Food and Drug AdministrationU.S.FDA0.005 ppm Occupational Safety and Health Administration,OSHA8405 μg/m3 8 PEL-TWA0.05 mg/m3 13 maximu m contaminant goal,MCL0.005 mg/L5 ppb Occupational Safety and H ealth Admission, OSHA8permissible exposure limit, PEL100 ppm8 200 ppm2300 ppm5 National Institute for Occupational Safety and Health, NIOSH recommended exposure limitREL 2 ppm (60REL25 ppm (10 8 PEL-TWA50 ppm269 mg/m3 14 Occupational Safety and H ealth Administration, OSHA8 400.005 mg/m3 U.S.EPA 0.003 mg/kg/day 600.18 mg 8 PEL-TWA1 mg/m3 0.05 mg/m3 405 111 111 1913IARC152 IARC5 5 / 5 5 / 1315 73766052462 74A.B.C.D.E.F. 92西西1175 315 使 ° 248045)24 76500 ppbv( 5 77) 5 退5 1913使 5 1571124 W=3A(AW 37) 710192058088 2603.23547871 112%312.392603.2354X12%=312.39347.73237813.36% 712W=3AA W)W 153.07(32603.2354)= 153.07)50079 5 5 20174425 ppm46 ppmTSP15 mg/Nm3107 65485 5 19131913 1913 1913 22191 3 17169-172 1913:5IARCIARC511 11511 68 5 1095187997沿12528(8083)98 10129(84)31102105 277 2851 (使470 10775 19101沿 161 529 調 5 100 8210181稿 731 100沿 西西10SO3.145.19 ppb SO30 ppbSO 250 ppb10941933.36 ppb140 ppbSO 75 ppb30 ppb西西 SO75 ppb使西西100SO 西92 9922537 101 2883)10 20082010199920014.071020203 02883 300345-346 C52 19992001(3)2008 2010(3西0.430.380.320.3968)4.07 (68) 1999200120082010 西20000.150.140.14(684.07 103 尿尿1051228 69尿尿尿 使5(1071031143 12212370西5 2019 COVID-19 10771610700554854911071122 10771610700554854911071122A-1A-5499 4484使 20 184210039012 205 IARC1 52IARC5 104104 5 5 -8 2000200020005 5 1/21105 3-35: 0.073/使25.7 ppb1/2 MDL 0.052 /0.017 /0.004 / 5 退1913使 5 48(121-12565115-222 101CEMS P101P201P401CEMS24CEMS15107 63115-222 CEMS64223-234 636465235 48(121-12565115-222 10711.935.548.065 5485 5 66237-386515102619237 67387 67662-1242.7382-383 662-1 662-7662-91662-105662-110662-117 80 88101 153.07500 12%13.36% 1913退51913 使 1841855 1841851841855 184185184185 28188 88421 8955184185953383) 9525504) 184 185 1841855 5 1913 5退 PM2.5VCMPM2.5VCMPM2.5VCM5 5 5 5 PM2.5 12389 PM2.542%西PM2.5 1041113 PM2.51357-35910 13 16-20PM2.51 10758 3 PM2.5 PM2.52361-362)TEDS9.0PM2.5NOx C03363-364106 926 PM2.5 PM2.5 200 4365-367)10612173 5369-373) PM2.5 PM2.5PM2.512.5% 20151116 6375) 調PM2.5PM2.5% PM2.5 PM2.5調 PM2.5 西PM2.55060 7 377)PM2.5 2015798379-381) PM2.5 20157 PM2.525%PM2.512.5%PM2.5 20159229383)3 104 1119PM2.51000 10385)11387PM2.5PM2.5 5PM2.5VCM 889494100 9%8%西12%32% ;941005%16%西25%48%貿 調 RCA51913 RCA1071 34穿 RCA8193 94110 RCA 97 1 95CHEMOSPHERE 1481502332363) 調 調 PCDD/PCDF251 260301137 RCA 5 5 19135 1913 1073 1952 195 195 5 10西24412 92164 5 5 975 5 5 5 5 104 1.27×l0西1.64l0 1010 10 10 10 cancer risk[1010]12) 10 102324稿調1 0 101016 427-428 1010 l0 10 11010261010 10-6 10-4()110102611911 1010 使101 10 l010 (40 CFR 300.430.17429-436 1010 10 1.2 7l0西1.64l0 1010 4 5 837 Best Available Control Technology, BACT 500153.0713.36%12% 51913 1010 (78.07)36524 10 Risk=LADDtotal SFRisk=CUnit Risk LADDtotal (mg/kg/day) LADD4-544-5518439-440 LADD102-10478.07year78.073651.2710 西1.64l0 西78.0736524381.27l078.07 101.27西1.64l0 78.07101.64 110 78.0738 5 西4 5 1010 94415滿20 78.07 1.27l0西1 .64l020 40%50%1010 8040%1939.5%2050%21 40%50%78.0738 1.27l0西1.64l0 1010 105 5 稿 稿 5 : 5 24412 5 5 119212329 ;24 27303428西簿197203-207 213-221225-241245-251257-261263-308313-319323-331337-344319-321327331335-367282-285288294-30539-47; ; 16117 118 11921232829 西; 24273034 588西199994西2005 5 470-471 1,3-1,2-1,3-2--1,2- 1,1,2,2-385 104-3 723.2.3 (): 3.600/0.003/9911180990102024 ;3.2.10 3.2.10-1(1/2)12 0.003100% 3-663-151;():38 ND377-4 537 5 [a] IARC1 ; 2A ; 1,2 -1,1,2,2- 2BIARCU.S. EPAZhao105545107-375331-363IARC2A2B5IARC2A2B 2 5 1841218519131941955 ;518411855? 262828188 184 使使28188 184 108 20355 184 184 5184 12185 1841851841855 1841277 5 5 8929277 277 使277調 使調107 2675使5 調277 10713 4RCA: 使 465;971:Threshold DoseThreshold Dose473;954RCA: 21-34;RCA : DNA DNA 535 5IARC12A2B 5 : 5 201211611 507 ; IARC111 509-552 411-416479-480:Dose Response Assessment (NRC1 983); RfD (reference dose)RfC(reference co ncentration);(slope factor) : No-observed-adverse effectlevel, NOAELLowest-obs erved-adverse effect level, LOAEL ()調( ) (Polycyclic Aromatic Hydrocarbons, PAHs)() 綿(toxicokinetics)( physiological basedpharmacokinetics, PBPK) ; () 5 西5 : 104-6調 : 1995200020002000; 2000; 20002000 ;7-6調:調 1989200019892008: 198920101989200019892010 19892000 20002000; 200020002000稿 稿 1.1:調 1-1 1-11-18 94107 157-185 26.7335.88 西32.0137.77 西10778110221.135.0 21.038.523.839.221.935.1; C52 : 199920013200820103 西0. 430.380.320.390.420.360.290.3799-103使西 104 10464107.957/105.824/ 98.02101.871/ 88.311/ 72.175/ -2;98VOCs 2-69 97沿19810155-34671-87102105 347-484 5 : 1015: 調::100000-0000 0000-00004.071020 2030COPD100000-00000000-00002.0110202030345-346 ;102 10A滿35 (西0000-0000 西0000-00002.8235 3.5435C9.04357 C52 ; 100 10181稿 731100沿 西西10SO3.145.19 ppb SO30 ppbSO 250 ppb10941933.36 ppb140 ppb SO75 ppb3 0 ppb西 西SO75 ppb使西西100SO 西92 99 537 調104 調107調 調調107西108調調23調2 11109731090047697調調 237-271 調5 5 18411855 18421855? 1842使使使1031242 1 1842 100102724 10493 529946141048182012231 224233111 241 2 53495-506517-528121734639639047348448994891041052022323243111 1222 40507-509507-516 4 246255266275948181048182023 3111291212511-515503-5052 17187948181048182023243212517-519 499-501 5 18425 5 51842 調5 277 5 1842185 5 19135? 使使1913 :使 使使使107803 : 使使使使使使 : 使使 5 55138-2085 5 5 1913 19135 5 5 5 1951352920? 119212328528195135? 19513 11921232855 19513 5 2 5 5 195135 202935285 19515? 195192164 ; 5 西 ; 500 ; 1042-17 西西5 5 104 1.27×l0西1.64l0 -4 7-4 1010 : 7410 413 ; 5cancer risk[ 1010]41 4;102324稿 調10 1010 427 1010 l0 10; 西 1:risk characterization 420 203 : : 3.2.2 : 滿3-40469 80% 80% 1.2 × 3-41471 3.2.3: 1021023-60465 ;:7-2 467 3.2.8::98 : ; 3-138473 4.5UncertaintyAnalysis.3 : 78.07102-104365 4-86475 1 104 ;989910120X2030X30; 1116206 97沿1 98101102105 5 5 5 195135 184121851913194195135 :         111    7     12   廿         111    7     12    1 0 2 00000 3 4 00 5 000 6 00 7 0000 8 0000 9 10 11 0001 12 0000 13 14 00 15 0000 16 0000 17 00000 18 001 19 20 21 0002 22 23 24 000 25 00 26 00 27 000 28 001 29 0006 30 00 31 00 32 00000 33 0000 34 000000 35 00000 1 500,000 200,000 700,000 109117 2 500,000 200,000 700,000 3 500,000 200,000 700,000 4 500,000 200,000 700,000 5 500,000 200,000 700,000 6 500,000 200,000 700,000 7 500,000 200,000 700,000 8 500,000 200,000 700,000 9 500,000 200,000 700,000 10 500,000 200,000 700,000 11 500,000 200,000 700,000 12 500,000 200,000 700,000 13 500,000 200,000 700,000 14 500,000 200,000 700,000 15 500,000 200,000 700,000 16 500,000 200,000 700,000 17 500,000 200,000 700,000 18 500,000 200,000 700,000 19 500,000 200,000 700,000 20 500,000 200,000 700,000 21 500,000 200,000 700,000 500,000 200,000 700,000 22 500,000 200,000 700,000 23 500,000 200,000 700,000 24 1,300,000 200,000 1,500,000 109117 25 1,300,000 200,000 1,500,000 26 1,300,000 200,000 1,500,000 27 1,300,000 200,000 1,500,000 28 1,300,000 200,000 1,500,000 29 500,000 500,000 30 1,300,000 200,000 1,500,000 31 1,300,000 200,000 1,500,000 32 1,300,000 200,000 1,500,000 33 1,300,000 200,000 1,500,000 34 1,300,000 200,000 1,500,000 35 1,300,000 200,000 1,500,000